HEPACAM2

Summary

HEPACAM2 (HEPACAM family member 2, HGNC:27364) is a protein-coding gene on chromosome 7q21.2, encoding HEPACAM family member 2 (A8MVW5). Required during prometaphase for centrosome maturation.

This gene encodes a protein related to the immunoglobulin superfamily that plays a role in mitosis. Knockdown of this gene results in prometaphase arrest, abnormal nuclear morphology and apoptosis. Poly(ADP-ribosylation) of the encoded protein promotes its translocation to centrosomes, which may stimulate centrosome maturation. A chromosomal deletion including this gene may be associated with myeloid leukemia and myelodysplastic syndrome in human patients.

Source: NCBI Gene 253012 — RefSeq curated summary.

At a glance

• Gene–disease (curated): Tourette syndrome (No Known Disease Relationship, GenCC)
• Clinical variants (ClinVar): 76 total
• MANE Select transcript: NM_001039372

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:27364
Approved symbol	HEPACAM2
Name	HEPACAM family member 2
Location	7q21.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ38683
Ensembl gene	ENSG00000188175
Ensembl biotype	protein_coding
OMIM	614133
Entrez	253012

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 5 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000341723, ENST00000394468, ENST00000440868, ENST00000453812, ENST00000492616, ENST00000890314

RefSeq mRNA: 5 — MANE Select: NM_001039372 NM_001039372, NM_001288804, NM_001288810, NM_001346642, NM_198151

CCDS: CCDS43616, CCDS5629, CCDS75631, CCDS75632

Canonical transcript exons

ENST00000394468 — 10 exons

Exon	Start	End
ENSE00001366850	93208580	93208876
ENSE00001369026	93197373	93197397
ENSE00001381094	93215401	93215685
ENSE00001518563	93219101	93219451
ENSE00001518564	93226368	93226469
ENSE00003481961	93197485	93197610
ENSE00003558841	93192254	93192363
ENSE00003562277	93195828	93195901
ENSE00003672854	93197241	93197278
ENSE00003893246	93188534	93189270

Expression profiles

Bgee: expression breadth ubiquitous, 129 present calls, max score 98.15.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 2.9072 / max 1445.9033, expressed in 79 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
84865	2.8183	68
84864	0.0435	15
84863	0.0280	11
84861	0.0174	4

Top tissues by expression

233 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ileal mucosa	UBERON:0000331	98.15	gold quality
mucosa of sigmoid colon	UBERON:0004993	98.14	gold quality
colonic mucosa	UBERON:0000317	97.16	gold quality
rectum	UBERON:0001052	96.67	gold quality
islet of Langerhans	UBERON:0000006	95.21	gold quality
palpebral conjunctiva	UBERON:0001812	92.81	gold quality
mucosa of transverse colon	UBERON:0004991	90.74	gold quality
jejunal mucosa	UBERON:0000399	88.82	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	87.12	gold quality
duodenum	UBERON:0002114	86.67	gold quality
kidney epithelium	UBERON:0004819	83.23	silver quality
transverse colon	UBERON:0001157	82.73	gold quality
small intestine Peyer’s patch	UBERON:0003454	82.12	gold quality
small intestine	UBERON:0002108	81.21	gold quality
adult mammalian kidney	UBERON:0000082	80.16	gold quality
colonic epithelium	UBERON:0000397	79.87	gold quality
metanephros cortex	UBERON:0010533	77.53	gold quality
kidney	UBERON:0002113	76.07	gold quality
intestine	UBERON:0000160	75.37	gold quality
pancreas	UBERON:0001264	74.96	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	74.10	gold quality
pituitary gland	UBERON:0000007	74.07	gold quality
cortex of kidney	UBERON:0001225	73.85	gold quality
bronchial epithelial cell	CL:0002328	73.42	gold quality
large intestine	UBERON:0000059	73.38	gold quality
jejunum	UBERON:0002115	72.65	gold quality
colon	UBERON:0001155	72.29	gold quality
bronchus	UBERON:0002185	72.16	gold quality
adenohypophysis	UBERON:0002196	70.92	gold quality
renal medulla	UBERON:0000362	70.18	gold quality

Single-cell (SCXA)

Detected in 9 experiment(s), a significant marker in 8.

Experiment	Marker?	Max mean expression
E-MTAB-5061	yes	2859.69
E-CURD-114	yes	310.15
E-HCAD-38	yes	272.00
E-CURD-46	yes	231.07
E-GEOD-125970	yes	36.32
E-CURD-119	yes	18.16
E-MTAB-8410	yes	14.04
E-HCAD-31	no	3.23
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

45 targeting HEPACAM2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-499A-5P	99.98	70.79	1323
HSA-MIR-4803	99.98	71.99	3117
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-8087	99.90	69.55	1351
HSA-MIR-605-3P	99.88	69.22	1833
HSA-MIR-5003-3P	99.85	69.29	2517
HSA-MIR-3180-5P	99.82	69.12	2422
HSA-MIR-4420	99.82	70.08	1624
HSA-MIR-181B-2-3P	99.81	70.06	1646
HSA-MIR-181B-3P	99.81	70.06	1646
HSA-MIR-4255	99.72	67.70	1541
HSA-MIR-1179	99.71	68.70	1040
HSA-MIR-494-3P	99.70	71.45	2795
HSA-MIR-29B-2-5P	99.67	68.98	1726
HSA-MIR-26A-1-3P	99.64	66.81	788
HSA-MIR-26A-2-3P	99.64	66.82	786
HSA-MIR-6832-5P	99.58	64.82	1132
HSA-MIR-3682-3P	99.58	67.63	865
HSA-MIR-510-3P	99.54	70.06	2965
HSA-MIR-4728-3P	99.47	68.94	981

Literature-anchored findings (GeneRIF, showing 1)

• The data suggest that PARsylation of Miki by tankyrase-1 is a key initial event promoting prometaphase. (PMID:22864114)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	hepacam2	ENSDARG00000061365
mus_musculus	Hepacam2	ENSMUSG00000044156
rattus_norvegicus	Hepacam2	ENSRNOG00000009711

Paralogs (24): CEACAM21 (ENSG00000007129), CEACAM7 (ENSG00000007306), CEACAM1 (ENSG00000079385), CEACAM6 (ENSG00000086548), CEACAM4 (ENSG00000105352), CEACAM5 (ENSG00000105388), PSG8 (ENSG00000124467), CEACAM8 (ENSG00000124469), HEPACAM (ENSG00000165478), PSG6 (ENSG00000170848), CEACAM3 (ENSG00000170956), PSG9 (ENSG00000183668), CEACAM19 (ENSG00000186567), PSG5 (ENSG00000204941), CEACAM18 (ENSG00000213822), CEACAM16 (ENSG00000213892), VSTM5 (ENSG00000214376), PSG3 (ENSG00000221826), PSG7 (ENSG00000221878), PSG1 (ENSG00000231924), PSG2 (ENSG00000242221), PSG11 (ENSG00000243130), PSG4 (ENSG00000243137), CEACAM20 (ENSG00000273777)

Protein

Protein identifiers

HEPACAM family member 2 — A8MVW5 (reviewed: A8MVW5)

Alternative names: Mitotic kinetics regulator

All UniProt accessions (2): A8MVW5, C9JN07

UniProt curated annotations — full annotation on UniProt →

Function. Required during prometaphase for centrosome maturation. Following poly-ADP-ribosylation (PARsylation) by TNKS, translocates from the Golgi apparatus to mitotic centrosomes and plays a key role in the formation of robust microtubules for prompt movement of chromosomes: anchors AKAP9/CG-NAP, a scaffold protein of the gamma-tubulin ring complex and promotes centrosome maturation.

Subcellular location. Golgi apparatus membrane. Cytoplasm. Cytoskeleton. Spindle. Microtubule organizing center. Centrosome. Midbody.

Tissue specificity. Widely expressed.

Post-translational modifications. Poly-ADP-ribosylated (PARsylated) by tankyrase TNKS during late G2 and prophase, leading to translocation to mitotic centrosomes. N-glycosylated.

Isoforms (3)

UniProt ID	Names	Canonical?
A8MVW5-1	1	yes
A8MVW5-2	2
A8MVW5-3	3

RefSeq proteins (5): NP_001034461, NP_001275733, NP_001275739, NP_001333571, NP_937794 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003598	Ig_sub2	Domain
IPR003599	Ig_sub	Domain
IPR007110	Ig-like_dom	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR052280	HEPACAM_domain	Family

Pfam: PF13927

UniProt features (18 total): glycosylation site 4, sequence variant 3, disulfide bond 2, splice variant 2, domain 2, signal peptide 1, chain 1, sequence conflict 1, transmembrane region 1, topological domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-A8MVW5-F1	78.76	0.55

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (2): 170–219, 270–315

Glycosylation sites (4): 85, 129, 165, 320

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 120 (showing top): GGGTGGRR_PAX4_03, GOCC_MICROTUBULE_ORGANIZING_CENTER, GOCC_CENTROSOME, HNF1_01, SOX5_01, GOCC_SPINDLE, GOCC_MITOTIC_SPINDLE, GOBP_CELL_DIVISION, GOCC_MIDBODY, GOBP_CELL_CYCLE_PROCESS, NIKOLSKY_MUTATED_AND_AMPLIFIED_IN_BREAST_CANCER, PR_Q2, PR_01, SENGUPTA_NASOPHARYNGEAL_CARCINOMA_WITH_LMP1_UP, MIKKELSEN_MEF_ICP_WITH_H3K27ME3

GO Biological Process (2): centrosome cycle (GO:0007098), cell division (GO:0051301)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (10): Golgi membrane (GO:0000139), nucleoplasm (GO:0005654), Golgi apparatus (GO:0005794), centrosome (GO:0005813), spindle (GO:0005819), midbody (GO:0030496), mitotic spindle (GO:0072686), cytoplasm (GO:0005737), cytoskeleton (GO:0005856), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
intracellular membraneless organelle	2
cell cycle process	1
microtubule organizing center organization	1
cellular process	1
binding	1
Golgi apparatus	1
bounding membrane of organelle	1
nuclear lumen	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
centriole	1
microtubule organizing center	1
microtubule cytoskeleton	1
spindle	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

996 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
HEPACAM2	VPS50	Q96JG6	652
HEPACAM2	SAMD9L	Q8IVG5	620
HEPACAM2	SAMD9	Q5K651	550
HEPACAM2	TNKS	O95271	497
HEPACAM2	TNKS2	Q9H2K2	485
HEPACAM2	FAM133B	Q5BKY9	483
HEPACAM2	CALCR	P30988	476
HEPACAM2	FGFR1	P11362	458
HEPACAM2	SERPINB12	Q96P63	454
HEPACAM2	NAPG	Q99747	450
HEPACAM2	CDK6	Q00534	443
HEPACAM2	FBXO43	Q4G163	439
HEPACAM2	RBM48	Q5RL73	438
HEPACAM2	UBXN2B	Q14CS0	430
HEPACAM2	HEMGN	Q9BXL5	420

IntAct

2 interactions, top by confidence:

A	B	Type	Score
HEPACAM2	PIK3R2	psi-mi:“MI:0914”(association)	0.350

BioGRID (81): NDFIP1 (Affinity Capture-MS), DNAJC11 (Affinity Capture-MS), MFAP3 (Affinity Capture-MS), PLEKHH3 (Affinity Capture-MS), ACVR2A (Affinity Capture-MS), HMGCR (Affinity Capture-MS), CYB5R1 (Affinity Capture-MS), ERO1LB (Affinity Capture-MS), RDH11 (Affinity Capture-MS), WDR44 (Affinity Capture-MS), RELT (Affinity Capture-MS), CD320 (Affinity Capture-MS), MAP4K4 (Affinity Capture-MS), UPK3BL (Affinity Capture-MS), BMPR1A (Affinity Capture-MS)

ESM2 similar proteins: A0JM41, A2VD98, A6QQC6, A8MVW5, B0CLX4, B6ZK76, B6ZK77, O60487, O70255, O88324, O88775, O95976, P01832, P03228, P06907, P08920, P08921, P09619, P0C6B7, P0C6N0, P0CW72, P10522, P20938, P21995, P25189, P27573, P37301, P37998, P59823, P59824, P86176, Q01151, Q4VAH7, Q5EAB0, Q5R804, Q640U3, Q6PCB8, Q6WEB5, Q80UL9, Q86XK7

Diamond homologs: A4FUY1, A6QQC6, A8MVW5, D3YXG0, D3ZB51, D3ZQE1, E9PZ19, O08775, P13595, P13596, P16573, P31809, P35968, P52583, Q00889, Q14CZ8, Q3KPI0, Q4VAH7, Q52KR2, Q62845, Q640R3, Q69Z26, Q9D2Z1, Q9HBG7, Q9UPX0, Q5STE3, Q63111, Q640U3, Q6MZW2, Q00888, Q8BFR2, Q8N475, A0A0B4J1L0, A0A140LHF2, E9QA28, O75871, P06731, P11464, P11465, P13688

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

76 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	59
Likely benign	4
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

1519 predictions. Top by Δscore:

Variant	Effect	Δscore
7:93192252:A:AC	donor_gain	1.0000
7:93192253:C:CC	donor_gain	1.0000
7:93192253:CT:C	donor_gain	1.0000
7:93195771:CACCT:C	donor_gain	1.0000
7:93195797:T:TA	donor_gain	1.0000
7:93197480:CCTA:C	donor_loss	1.0000
7:93197481:CTA:C	donor_loss	1.0000
7:93197482:TA:T	donor_loss	1.0000
7:93197483:ACC:A	donor_loss	1.0000
7:93197484:C:CA	donor_loss	1.0000
7:93197606:CAGTC:C	acceptor_gain	1.0000
7:93197608:GTC:G	acceptor_gain	1.0000
7:93197609:TC:T	acceptor_gain	1.0000
7:93197609:TCCTA:T	acceptor_loss	1.0000
7:93197610:CC:C	acceptor_gain	1.0000
7:93197611:C:CC	acceptor_gain	1.0000
7:93197611:CT:C	acceptor_loss	1.0000
7:93197612:T:A	acceptor_loss	1.0000
7:93215430:T:A	donor_gain	1.0000
7:93189870:C:CT	donor_gain	0.9900
7:93192246:GTAC:G	donor_loss	0.9900
7:93192247:TACT:T	donor_loss	0.9900
7:93192248:ACTT:A	donor_loss	0.9900
7:93192250:T:TC	donor_loss	0.9900
7:93192251:TACT:T	donor_loss	0.9900
7:93192252:A:AT	donor_loss	0.9900
7:93192252:ACT:A	donor_gain	0.9900
7:93192253:CTC:C	donor_gain	0.9900
7:93192361:GATCT:G	acceptor_gain	0.9900
7:93192362:ATCTA:A	acceptor_gain	0.9900

AlphaMissense

3035 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:93219329:A:G	W68R	0.996
7:93219329:A:T	W68R	0.996
7:93208746:C:A	W282C	0.995
7:93208746:C:G	W282C	0.995
7:93208748:A:G	W282R	0.995
7:93208748:A:T	W282R	0.995
7:93215572:A:G	W182R	0.995
7:93215572:A:T	W182R	0.995
7:93215570:C:A	W182C	0.994
7:93215570:C:G	W182C	0.994
7:93219211:A:G	L107P	0.994
7:93208782:A:C	C270W	0.991
7:93219106:A:T	V142D	0.991
7:93208784:A:G	C270R	0.990
7:93215461:A:G	C219R	0.990
7:93215608:A:G	C170R	0.990
7:93219112:A:T	V140D	0.990
7:93219173:A:C	Y120D	0.989
7:93219160:A:T	V124D	0.988
7:93208647:G:C	C315W	0.987
7:93208783:C:T	C270Y	0.987
7:93215460:C:G	C219S	0.987
7:93215461:A:T	C219S	0.987
7:93208635:G:C	N319K	0.986
7:93208635:G:T	N319K	0.986
7:93208648:C:G	C315S	0.986
7:93208649:A:T	C315S	0.986
7:93208771:G:A	S274F	0.986
7:93208772:A:G	S274P	0.986
7:93208783:C:G	C270S	0.986

dbSNP variants (sampled 300 via entrez): RS1000022155 (7:93222801 C>A), RS1000176690 (7:93195104 CA>C), RS1000206833 (7:93197128 A>G,T), RS1000279350 (7:93190906 C>A,T), RS1000322300 (7:93197508 C>T), RS1000628266 (7:93220886 C>T), RS1000800119 (7:93213231 G>A,C), RS1000870417 (7:93214926 T>G), RS1000914570 (7:93220518 A>C), RS1001002593 (7:93200211 AT>A,ATT), RS1001015156 (7:93200563 C>A,G,T), RS1001391937 (7:93209489 C>T), RS1001430849 (7:93215812 G>A,T), RS1001616429 (7:93224514 C>A,T), RS1001722576 (7:93232593 T>A)

Disease associations

OMIM: gene MIM:614133 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
Tourette syndrome	No Known Disease Relationship	Unknown

Mondo (3): prostate cancer (MONDO:0008315), breast ductal adenocarcinoma (MONDO:0005590), Tourette syndrome (MONDO:0007661)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750
D005879	Tourette Syndrome	C10.228.140.079.898; C10.228.662.825.800; C10.574.500.850; C16.320.400.820; F03.625.992.850

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

17 total (human), top 17 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Tobacco Smoke Pollution	decreases expression, affects expression	2
bisphenol F	decreases methylation	1
bisphenol A	affects cotreatment, decreases methylation	1
terbufos	decreases methylation	1
sodium arsenite	increases expression	1
perfluorooctanoic acid	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects cotreatment, affects response to substance, increases expression	1
perfluorooctane sulfonic acid	increases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Benzo(a)pyrene	increases methylation, affects methylation	1
Fonofos	decreases methylation	1
Lipopolysaccharides	affects response to substance, increases expression, affects cotreatment	1
Parathion	decreases methylation	1
Valproic Acid	decreases methylation	1
Aflatoxin B1	decreases methylation	1
Aflatoxin M1	decreases expression	1
Antirheumatic Agents	increases expression	1

Clinical trials (associated diseases)

483 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00152750	PHASE4	UNKNOWN	Study of Clonidine on Sleep Architecture in Children With Tourette’s Syndrome (TS) and Comorbid ADHD
NCT00226824	PHASE4	TERMINATED	Safety Study of Galantamine in Tic Disorders
NCT00241176	PHASE4	COMPLETED	Open Label Trial of Aripiprazole in Children and Adolescents With Tourette’s Disorder
NCT00370838	PHASE4	COMPLETED	Comparison of Keppra and Clonidine in the Treatment of Tics
NCT01018056	PHASE4	COMPLETED	Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission
NCT01547000	PHASE4	COMPLETED	Guanfacine in Children With Tic Disorders
NCT03239210	PHASE4	COMPLETED	Effects of Ondansetron in Obsessive-compulsive and Tic Disorders
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy